Blockchain Registration Transaction Record

OS Therapies Advances Toward Global Approval for Osteosarcoma Treatment

OS Therapies (NYSE: OSTX) gains regulatory clarity as EMA initiates rolling review for OST-HER2 in osteosarcoma. Key catalysts in 2026 include survival data, FDA meetings, and potential approval. Learn more from Stonegate Capital Partners.

This news matters because it signals a potential breakthrough for patients with recurrent osteosarcoma, a rare and aggressive cancer with limited treatment options. The regulatory clarity and upcoming data readouts could accelerate access to OST-HER2, offering hope to patients and families. For investors, the dense catalyst calendar and potential PRV valuation represent significant upside, making OS Therapies a key stock to watch in the biotech space.